Patents by Inventor Samir Das

Samir Das has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE
    Publication number: 20260042847
    Abstract: Antibody constructs engineered to introduce at least one cysteine insertion mutation (“cysteine engineered antibody constructs”) are described. The inserted cysteine residue(s) may be used as a site for conjugation of one or more active agents to the antibody construct to provide conjugates, such as antibody-drug conjugates.
    Type: Application
    Filed: March 25, 2022
    Publication date: February 12, 2026
    Inventors: James R. Rich, Marlo Sanches, Samir Das, Patrick Farber
  • IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making
    Patent number: 12546785
    Abstract: The present application provides stable peptide-based IL-17F and IL-17A capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.
    Type: Grant
    Filed: June 15, 2023
    Date of Patent: February 10, 2026
    Assignees: Regeneron Pharmaceuticals, Inc., California Institute of Technology
    Inventors: Heather Agnew, Bert Tsunyin Lai, Suresh Mark Pitram, Blake Farrow, James R. Heath, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das
  • Il-17F-specific capture agents, compositions, and methods of using and making
    Patent number: 12517136
    Abstract: The present application provides stable peptide-based IL-17F capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: January 6, 2026
    Assignees: California Institute of Technology, Regeneron
    Inventors: James R. Heath, Heather Agnew, Blake Farrow, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das, Bert Tsunyin Lai, Suresh Mark Pitram
  • AKT-specific capture agents, compositions, and methods of using and making
    Patent number: 12480950
    Abstract: The present application provides stable peptide-based Akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including Akt capture agents, using iterative on-bead in situ click chemistry.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 25, 2025
    Assignees: Regeneron Pharmaceuticals, Inc., California Institute of Technology
    Inventors: James R. Heath, Arundhati Nag, Samir Das, Kaycie M. Deyle, Steven Wesley Millward, Paul Edward Kearney
  • ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE
    Publication number: 20250339552
    Abstract: Antibody-drug conjugates (ADCs) comprising an antibody construct that binds specifically binds human folate receptor alpha (FR?) (an anti-FR? antibody construct) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.
    Type: Application
    Filed: June 24, 2025
    Publication date: November 6, 2025
    Inventors: James R. RICH, Stuart Daniel BARNSCHER, Mark Edmund PETERSEN, Raffaele COLOMBO, Michael G. BRANT, Manuel Michel Auguste LASALLE, Rupert H. DAVIES, Dunja UROSEV, Sukhbir Singh KANG, Peter Wing Yiu CHAN, Samir DAS, Andrea HERNANDEZ ROJAS, Robert William GENE, Ada G. H. YOUNG, Samuel Oliver LAWN, Danny CHUI, Duncan BROWMAN, Brandon CLAVETTE
  • Antibody-drug conjugates targeting folate receptor alpha and methods of use
    Patent number: 12433952
    Abstract: Antibody-drug conjugates (ADCs) comprising an antibody construct that binds specifically binds human folate receptor alpha (FR?) (an anti-FR? antibody construct) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.
    Type: Grant
    Filed: May 29, 2024
    Date of Patent: October 7, 2025
    Assignee: Zymeworks BC Inc.
    Inventors: James R. Rich, Stuart Daniel Barnscher, Mark Edmund Petersen, Raffaele Colombo, Michael G. Brant, Manuel Michel Auguste Lasalle, Rupert H. Davies, Dunja Urosev, Sukhbir Singh Kang, Peter Wing Yiu Chan, Samir Das, Andrea Hernandez Rojas, Robert William Gene, Ada G. H. Young, Samuel Oliver Lawn, Danny Chui, Duncan Browman, Brandon Clavette
  • ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE
    Publication number: 20250295799
    Abstract: Described herein are antibody-drug conjugates (ADCs) comprising an antibody construct that binds human glypican 3 (GPC3) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.
    Type: Application
    Filed: April 8, 2025
    Publication date: September 25, 2025
    Inventors: Andrea Hernandez Rojas, Chayne L. Piscitelli, Stuart Daniel Barnscher, James R. Rich, Michael G. Brant, Raffaele Colombo, Samir Das, Manuel Michel Auguste Lasalle, Mark Edmund Petersen, Alex Man Lai Wu, Diego Arturo Alonzo Muniz, Dunja Urosev
  • AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
    Publication number: 20250264471
    Abstract: The present application provides stable peptide-based Akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including Akt capture agents, using iterative on-bead in situ click chemistry.
    Type: Application
    Filed: December 4, 2024
    Publication date: August 21, 2025
    Inventors: James R. HEATH, Arundhati NAG, Samir DAS, Kaycie M. DEYLE, Steven Wesley MILLWARD, Paul Edward KEARNEY
  • ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE
    Publication number: 20250235548
    Abstract: Described herein are antibody-drug conjugates (ADCs) comprising an antibody construct that binds human sodium-dependent phosphate transporter 2B (NaPi2b) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.
    Type: Application
    Filed: April 7, 2025
    Publication date: July 24, 2025
    Inventors: James R. Rich, Grant Raymond Wickman, Stuart Daniel Barnscher, Andrea Hernandez Rojas, Eric ESCOBAR-CABRERA, Michael G. Brant, Raffaele Colombo, Samir Das, Manuel Michel Auguste Lasalle, Mark Edmund Petersen, Robert William Gene, Samuel Oliver Lawn, Sukhbir Singh Kang, Danny Chui, Brandon Clavette, Duncan Browman, Gesa Volkers, Dunja Urosev
  • ANTIBODY DRUG-CONJUGATES TARGETING C-MET AND METHODS OF USE THEREOF
    Publication number: 20250222128
    Abstract: Antibody-drug conjugates (ADCs) comprising an antibody construct that specifically binds c-Met conjugated to one or more drugs, such as the auristatin analogue, compound 1, via a linker. Also described are anti-cMet antibody constructs that have been engineered to include one or more cysteine insertion mutations with each inserted cysteine residue providing a conjugation “handle” allowing for conjugation of a drug-linker to provide an ADC. Further described are multivalent drug-linkers comprising a plurality of the auristatin analogues suitable for use in the ADCs described herein.
    Type: Application
    Filed: March 26, 2025
    Publication date: July 10, 2025
    Inventors: Rupert H. Davies, James R. Rich, Graham Albert Edwin Garnett, Mario Sanches, Samir Das, Patrick Farber, Stuart Daniel Barnscher
  • PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
    Publication number: 20250130235
    Abstract: The present application provides stable peptide-based Akt capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing Akt capture agents using iterative on-bead in situ click chemistry.
    Type: Application
    Filed: July 26, 2024
    Publication date: April 24, 2025
    Inventors: James R. Heath, Arundhati Nag, Samir Das, Joseph O. Varghese, Ryan K. Henning
  • ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE
    Publication number: 20240424125
    Abstract: Antibody-drug conjugates (ADCs) comprising an antibody construct that binds specifically binds human folate receptor alpha (FR?) (an anti-FR? antibody construct) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.
    Type: Application
    Filed: May 29, 2024
    Publication date: December 26, 2024
    Inventors: James R. RICH, Stuart Daniel BARNSCHER, Mark Edmund PETERSEN, Raffaele COLOMBO, Michael G. BRANT, Manuel Michel Auguste LASALLE, Rupert H. DAVIES, Dunja UROSEV, Sukhbir Singh KANG, Peter Wing Yiu CHAN, Samir DAS, Andrea HERNANDEZ ROJAS, Robert William GENE, Ada G. H. YOUNG, Samuel Oliver LAWN, Danny CHUI, Duncan BROWMAN, Brandon CLAVETTE
  • IL-17F AND IL-17A-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
    Publication number: 20240337665
    Abstract: The present application provides stable peptide-based IL-17F and IL-17A capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.
    Type: Application
    Filed: June 15, 2023
    Publication date: October 10, 2024
    Inventors: Heather Agnew, Bert Tsunyin Lai, Suresh Mark Pitram, Blake Farrow, James R. Heath, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das
  • Method for passive wireless channel estimation in radio frequency network and apparatus for same
    Patent number: 12106173
    Abstract: A method, system and apparatus are provided for estimating at least one characteristic of a wireless communication channel between at least two passive backscattering radio frequency (RF) nodes, the method including measuring backscatter channel state information (BCSI) during communication between the at least two passive RF nodes; estimating, by at least one RF node of the at least two passive RF nodes, the at least one characteristic of the wireless communication channel based on the measured BCSI.
    Type: Grant
    Filed: September 19, 2023
    Date of Patent: October 1, 2024
    Assignee: The Research Foundation for The State University of New York
    Inventors: Milutin Stanaćević, Samir Das, Petar Djurić, Athalye Akshay, Ryoo Jihoon, Yasha Karimi
  • CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE
    Publication number: 20240269309
    Abstract: Camptothecin analogues of Formula (I) and conjugates comprising the camptothecin analogues are described. The camptothecin analogues and conjugates may be used as therapeutic agents, particularly in the treatment of cancer, an autoimmune disease or a viral infection.
    Type: Application
    Filed: May 27, 2022
    Publication date: August 15, 2024
    Inventors: Mark Edmund Petersen, Michael Brant, Raffaele Colombo, james R. Rich, Manuel Michel Auguste Lasalle, Stuart Barnscher, Samir Das
  • METHOD FOR PASSIVE WIRELESS CHANNEL ESTIMATION IN RADIO FREQUENCY NETWORK AND APPARATUS FOR SAME
    Publication number: 20240005112
    Abstract: A method, system and apparatus are provided for estimating at least one characteristic of a wireless communication channel between at least two passive backscattering radio frequency (RF) nodes, the method including measuring backscatter channel state information (BCSI) during communication between the at least two passive RF nodes; estimating, by at least one RF node of the at least two passive RF nodes, the at least one characteristic of the wireless communication channel based on the measured BCSI.
    Type: Application
    Filed: September 19, 2023
    Publication date: January 4, 2024
    Inventors: Milutin STANACEVIC, Samir DAS, Petar DJURIC, Athalye AKSHAY, Ryoo JIHOON, Yasha KARIMI
  • Method for passive wireless channel estimation in radio frequency network and apparatus for same
    Patent number: 11763106
    Abstract: A method, system and apparatus are provided for estimating characteristics of a wireless communication channel between at least two passive radio frequency (RF) nodes. Backscatter channel state information (BCSI) is measured during communication between the at least two passive RF nodes using the wireless communication channel. An RF node aggregates the measured BCSI and the aggregated BSCI is analyzed to detect at least one activity of a plurality of activities.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: September 19, 2023
    Assignee: The Research Foundation for The State University of New York
    Inventors: Milutin Stanacevic, Samir Das, Petar Djurić, Athalye Akshay, Ryoo Jihoon, Yasha Karimi
  • IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making
    Patent number: 11719705
    Abstract: The present application provides stable peptide-based IL-17F and IL-17A capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: August 8, 2023
    Assignees: INDI MOLECULAR, INC., CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Heather Agnew, Bert Tsunyin Lai, Suresh Mark Pitram, Blake Farrow, James R. Heath, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das
  • PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
    Publication number: 20230019342
    Abstract: The present application provides stable peptide-based Akt capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing Akt capture agents using iterative on-bead in situ click chemistry.
    Type: Application
    Filed: June 27, 2022
    Publication date: January 19, 2023
    Inventors: James R. Heath, Arundhati Nag, Samir Das, Joseph O. Varghese, Ryan K. Henning
  • CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS
    Publication number: 20220380409
    Abstract: Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1 Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.
    Type: Application
    Filed: June 20, 2022
    Publication date: December 1, 2022
    Inventors: James R. Heath, Rosemary Dyane Rohde, Arundhati Nag, Samir Das, Aiko Umeda